Compare KE Holdings Inc (BEKE) vs Bristol-Myers Squibb Co (BMY) Price & Performance

BEKE trades at $17.42, down 1.3% today but showing technical bullish signals with strong analyst support. The company reported mixed quarterly results with a Q1 2026 earnings beat but missed Q4 2025 expectations. Revenue declined from $94.6B in 2025 to $90.1B projected for 2026, though net profit margin improved to 3.76%. Technical indicators show bullish momentum with ADX signals supporting upward trend potential.

Outlook remains positive with 92% analyst buy ratings, though investors face risks from China's property market volatility and recent revenue contraction. The stock's valuation at P/E 38.5 appears elevated relative to growth, requiring sustained earnings improvement to justify current multiples. Cash flow trends show improvement with operating cash flow turning positive in 2026 projections.

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.